<DOC>
	<DOC>NCT01539642</DOC>
	<brief_summary>The purpose of this study is to compare the efficacy and safety of the Sufentanil NanoTab PCA System/15 mcg to the Placebo Sufentanil NanoTab PCA System for the management of acute moderate to severe post-operative pain after open abdominal surgery.</brief_summary>
	<brief_title>A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of the Sufentanil NanoTab PCA System/15 mcg (Zalviso™) for the Treatment of Post-Operative Pain in Patients After Open Abdominal Surgery</brief_title>
	<detailed_description />
	<mesh_term>Pain, Postoperative</mesh_term>
	<mesh_term>Sufentanil</mesh_term>
	<criteria>Male or female patients who are 18 years or older Patients who are scheduled to undergo an open abdominal surgery (including laparoscopicassisted) under general anesthesia or spinal anesthesia that does not include intrathecal opioids during the operation. Postsurgical patients who have been admitted to the PACU and are expected to remain hospitalized and to have acute postoperative pain requiring parenteral opioids for at least 48 hours after surgery. Patients who have taken an opioid for more than 30 consecutive days, at a daily dose of more than 15 mg of morphine (or equivalent), within the past 3 months prior to surgery (e.g. more than 3 doses per day of Vicodin®, Norco®, Lortab® with 5 mg hydrocodone per tablet). Patients with an allergy or hypersensitivity to opioids. Female patients who are pregnant or breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>In patient, post operative pain</keyword>
	<keyword>Adult post-operative inpatients who are expected to require parenteral opioid analgesia for at least 48 hours after open abdominal surgery</keyword>
</DOC>